Recent nanotechnological aspects and molecular targeting strategies for lung cancer therapy

1. Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7–3310.3322/caac.21708 ↗

2. Inamura K (2017) Lung cancer: understanding its molecular pathology and the 2015 WHO classification. Front Oncol 7:19310.3389/fonc.2017.00193 ↗

3. Maiuthed A, Chantarawong W, Chanvorachote P (2018) Lung cancer stem cells and cancer stem cell-targeting natural compounds. Anticancer Res 38:3797–380910.21873/anticanres.12663 ↗

4. Malhotra J, Malvezzi M, Negri E, La Vecchia C, Boffetta P (2016) Risk factors for lung cancer worldwide. Eur Respir J 48:889–90210.1183/13993003.00359-2016 ↗

5. Duma N, Santana-Davila R, Molina JR (2019) Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc 94:1623–164010.1016/j.mayocp.2019.01.013 ↗

6. Senoo S, Ninomiya K, Hotta K, Kiura K (2019) Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan. Int J Clin Oncol 24:461–46710.1007/s10147-019-01424-y ↗

7. Wang BY, Huang JY, Chen HC, Lin CH, Lin SH, Hung WH, Cheng YF (2020) The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients. J Cancer Res Clin Oncol 146:43–5210.1007/s00432-019-03079-8 ↗

8. Weissferdt A (2014) Large cell carcinoma of lung: on the verge of extinction? Semin Diagn Pathol 31:278–28810.1053/j.semdp.2014.06.005 ↗

9. Wang W, Hao Y, Liu Y, Li R, Huang DB, Pan YY (2021) Nanomedicine in lung cancer: current states of overcoming drug resistance and improving cancer immunotherapy. Wiley Interdiscip Rev Nanomedicine Nanobiotechnol 13:e165410.1002/wnan.1654 ↗

10. Hussain S (2016) Nanomedicine for treatment of lung cancer. Adv Exp Med Biol 890:137–14710.1007/978-3-319-24932-2_8 ↗

11. Kurmi BD, Kayat J, Gajbhiye V, Tekade RK, Jain NK (2010) Micro- and nanocarrier-mediated lung targeting. Expert Opin Drug Deliv 7:781–79410.1517/17425247.2010.492212 ↗

12. Kurmi BD, Paliwal SR (2022) Development and optimization of TPGS-based stealth liposome of doxorubicin using Box-Behnken design: characterization, hemocompatibility, and cytotoxicity evaluation in breast cancer cells. J Liposome Res 32:129–14510.1080/08982104.2021.1903034 ↗

13. Li S, Xu S, Liang X, Xue Y, Mei J, Ma Y, Liu Y, Liu Y (2021) Nanotechnology: breaking the current treatment limits of lung cancer. Adv Healthcare Mater 10:e210007810.1002/adhm.202100078 ↗

14. Kurmi BD, Paliwal R, Paliwal SR (2020) Dual cancer targeting using estrogen functionalized chitosan nanoparticles loaded with doxorubicin-estrone conjugate: a quality by design approach. Int J Biol Macromol 164:2881–289410.1016/j.ijbiomac.2020.08.172 ↗

15. Kandasamy G, Maity D (2021) Multifunctional theranostic nanoparticles for biomedical cancer treatments - a comprehensive review. Mater Sci Eng C, Mater Biol Appl 127:11219910.1016/j.msec.2021.112199 ↗

16. Petty WJ, Paz-Ares L (2023) Emerging strategies for the treatment of small cell lung cancer: a review. JAMA Oncol 9:419–42910.1001/jamaoncol.2022.5631 ↗

17. Yang S, Zhang Z, Wang Q (2019) Emerging therapies for small cell lung cancer. J Hematol Oncol 12:4710.1186/s13045-019-0736-3 ↗

18. de Scordilli M;Michelotti A, Bertoli E, De Carlo E, Del Conte A, Bearz A (2022) Targeted therapy and immunotherapy in early-stage non-small cell lung cancer: current evidence and ongoing trials. Int J Mol Sci 23:722210.3390/ijms23137222 ↗

19. Wu SG, Shih JY (2018) Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer 17:3810.1186/s12943-018-0777-1 ↗

20. Provencio M, Calvo V, Romero A, Spicer JD, Cruz-Bermúdez A (2022) Treatment sequencing in resectable lung cancer: the good and the bad of adjuvant versus neoadjuvant therapy. Am Soc Clin Oncol Educ Book 42:1–18

21. Roskoski R Jr (2019) Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res 139:395–41110.1016/j.phrs.2018.11.014 ↗

22. Du X, Shao Y, Qin HF, Tai YH, Gao HJ (2018) ALK-rearrangement in non-small-cell lung cancer (NSCLC). Thorac Cancer 9:423–43010.1111/1759-7714.12613 ↗

23. Proietti I, Skroza N, Michelini S, Mambrin A, Balduzzi V, Bernardini N, Marchesiello A, Tolino E, Volpe S, Maddalena P, Di Fraia M, Mangino G, Romeo G, Potenza C (2020) BRAF inhibitors: molecular targeting and immunomodulatory actions. Cancers 1210.3390/cancers12071823 ↗

24. Morris TA, Khoo C, Solomon BJ (2019) Targeting ROS1 rearrangements in non-small cell lung cancer: crizotinib and newer generation tyrosine kinase inhibitors. Drugs 79:1277–128610.1007/s40265-019-01164-3 ↗

25. Kim C, Giaccone G (2018) MEK inhibitors under development for treatment of non-small-cell lung cancer. Expert Opin Investig Drugs 27:17–3010.1080/13543784.2018.1415324 ↗

26. Markham A (2020) Pralsetinib: first approval. Drugs 80:1865–187010.1007/s40265-020-01427-4 ↗

27. Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, Heeroma K, Itoh Y, Cornelio G, Yang PC (2014) A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol : Off Publ Int Assoc Study Lung Cancer 9:154–16210.1097/JTO.0000000000000033 ↗

28. Rosell R, Morán T, Carcereny E, Quiroga V, Molina MA, Costa C, Benlloch S, Tarón M (2010) Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain. Clin Transl Oncol : Off Publ Fed Spanish Oncol Soc Nat Cancer Inst of Mexico 12:75–8010.1007/S12094-010-0473-0 ↗

29. Reguart N, Remon J (2015) Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors. Futur Oncol (London, England) 11:1245–125710.2217/fon.15.15 ↗

30. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113–12510.1056/NEJMoa1713137 ↗

31. Solassol I, Pinguet F, Quantin X (2019) FDA- and EMA-approved tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer: safety, tolerability, plasma concentration monitoring, and management. Biomolecules 910.3390/biom9110668 ↗

32. Naylor EC, Desani JK, Chung PK (2016) Targeted therapy and immunotherapy for lung cancer. Surg Oncol Clin N Am 25:601–60910.1016/j.soc.2016.02.011 ↗

33. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–238810.1056/NEJMoa0909530 ↗

34. Yasumuro O, Uchida S, Kashiwagura Y, Suzuki A, Tanaka S, Inui N, Watanabe H, Namiki N (2018) Changes in gefitinib, erlotinib and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in rats. Xenobiotica; Fate Foreign Compd Biol Syst 48:1106–111210.1080/00498254.2017.1396379 ↗

35. Li J, Zhao M, He P, Hidalgo M, Baker SD (2007) Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clinical cancer research : an official journal of the American Association for Cancer Research 13:3731–373710.1158/1078-0432.CCR-07-0088 ↗

36. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–24610.1016/S1470-2045(11)70393-X ↗

37. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C (2015) Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol : Off J Eur Soc Med Oncol 26:1877–188310.1093/annonc/mdv276 ↗

38. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong KK (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27:4702–471110.1038/onc.2008.109 ↗

39. Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O’Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV (2015) Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 16:141–15110.1016/S1470-2045(14)71173-8 ↗

40. Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA (2017) Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376:629–64010.1056/NEJMoa1612674 ↗

41. Onitsuka T, Uramoto H, Nose N, Takenoyama M, Hanagiri T, Sugio K, Yasumoto K (2010) Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung cancer (Amsterdam, Netherlands) 68:198–20310.1016/j.lungcan.2009.05.022 ↗

42. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riely GJ (2013) Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res : An Off J Am Assoc Cancer Res 19:2240–224710.1158/1078-0432.CCR-12-2246 ↗

43. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378:2288–230110.1056/NEJMoa1716948 ↗

44. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561–56610.1038/nature05945 ↗

45. Shaw AT, Solomon B (2011) Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res : An Off J Am Assoc Cancer Res 17:2081–208610.1158/1078-0432.CCR-10-1591 ↗

46. Dziadziuszko R, Mok T, Peters S, Han JY, Alatorre-Alexander J, Leighl N, Sriuranpong V, Pérol M, de Castro Junior G, Nadal E, de Marinis F, Frontera OA, Tan DSW, Lee DH, Kim HR, Yan M, Riehl T, Schleifman E, Paul SM, Mocci S, Patel R, Assaf ZJ, Shames DS, Mathisen MS, Gadgeel SM (2021) Blood First Assay Screening Trial (BFAST) in treatment-naive advanced or metastatic NSCLC: initial results of the phase 2 ALK-positive cohort. J Thorac Oncol : Off Publ Int Assoc Study Lung Cancer 16:2040–205010.1016/j.jtho.2021.07.008 ↗

47. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. The New England J Med 2015, 373, 158210.1056/NEJMx150034 ↗

48. Remon J, Pignataro D, Novello S, Passiglia F (2021) Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer. Cancer Treat Rev 95:10217810.1016/j.ctrv.2021.102178 ↗

49. Peters S, Mok TS, Gadgeel SM, Rosell R, Dziadziuszko R, Kim D-W, Perol M, Ou S-HI, Shaw AT, Bordogna W (2020) Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC. Am Soc Clin Oncol10.1200/JCO.2020.38.15_suppl.9518 ↗

50. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T (2017) Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377:829–83810.1056/NEJMoa1704795 ↗

51. Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, Hochmair M, Cortot AB, Tsai CM, Moro-Sibilot D, Campelo RG, McCulloch T, Sen P, Dugan M, Pantano S, Branle F, Massacesi C, de Castro G Jr(2017) First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet (London, England) 389:917-92910.1016/S0140-6736(17)30123-X ↗

52. Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ou SI, Shaw AT (2018) Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol 19:1654–166710.1016/S1470-2045(18)30649-1 ↗

53. Lin JJ, Zhu VW, Schoenfeld AJ, Yeap BY, Saxena A, Ferris LA, Dagogo-Jack I, Farago AF, Taber A, Traynor A, Menon S, Gainor JF, Lennerz JK, Plodkowski AJ, Digumarthy SR, Ou SI, Shaw AT, Riely GJ (2018) Brigatinib in patients with alectinib-refractory ALK-positive NSCLC. J Thor Oncol : Off Publ Int Assoc Study Lung Cancer 13:1530–153810.1016/j.jtho.2018.06.005 ↗

54. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol : Off J Am Soc Clin Oncol 30:863–87010.1200/JCO.2011.35.6345 ↗

55. Davies KD, Doebele RC (2013) Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res : An Off J Am Assoc Cancer Res 19:4040–404510.1158/1078-0432.CCR-12-2851 ↗

56. Singal G, Miller PG, Agarwala V, Li G, Kaushik G, Backenroth D, Gossai A, Frampton GM, Torres AZ, Lehnert EM, Bourque D, O’Connell C, Bowser B, Caron T, Baydur E, Seidl-Rathkopf K, Ivanov I, Alpha-Cobb G, Guria A, He J, Frank S, Nunnally AC, Bailey M, Jaskiw A, Feuchtbaum D, Nussbaum N, Abernethy AP, Miller VA (2019) Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database. JAMA 321:1391–139910.1001/jama.2019.3241 ↗

57. Chiari R, Ricciuti B, Landi L, Morelli AM, Delmonte A, Spitaleri G, Cortinovis DL, Lamberti G, Facchinetti F, Pilotto S, Verusio C, Chella A, Bonanno L, Galetta D, Cappuzzo F (2020) ROS1-rearranged non-small-cell lung cancer is associated with a high rate of venous thromboembolism: analysis from a phase II, prospective, multicenter, two-arms trial (METROS). Clin Lung Cancer 21:15–2010.1016/j.cllc.2019.06.012 ↗

58. Ng TL, Smith DE, Mushtaq R, Patil T, Dimou A, Yang S, Liu Q, Li X, Zhou C, Jones RT, Tu MM, Yan F, Bowman IA, Liu SV, Newkirk S, Bauml J, Doebele RC, Aisner DL, Gao D, Ren S, Camidge DR (2019) ROS1 gene rearrangements are associated with an elevated risk of peridiagnosis thromboembolic events. J Thorac Oncol : Off Publ Int Assoc Study Lung Cancer 14:596–60510.1016/j.jtho.2018.12.001 ↗

59. Ou SI, Zhu VW (2019) CNS metastasis in ROS1+ NSCLC: an urgent call to action, to understand, and to overcome. Lung cancer (Amsterdam, Netherlands) 130:201–20710.1016/j.lungcan.2019.02.025 ↗

60. Liu Y, Liu T, Li N, Wang T, Pu Y, Lin R (2019) Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib. Lung cancer (Amsterdam, Netherlands) 129:92–9410.1016/j.lungcan.2018.12.011 ↗

61. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve SM, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ (2014) Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371:1963–197110.1056/NEJMoa1406766 ↗

62. Wu YL, Yang JC, Kim DW, Lu S, Zhou J, Seto T, Yang JJ, Yamamoto N, Ahn MJ, Takahashi T, Yamanaka T, Kemner A, Roychowdhury D, Paolini J, Usari T, Wilner KD, Goto K (2018) Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer. J Clini Oncol : Off J Am Soc Clin Oncol 36:1405–141110.1200/JCO.2017.75.5587 ↗

63. Gainor JF, Tseng D, Yoda S, Dagogo-Jack I, Friboulet L, Lin JJ, Hubbeling HG, Dardaei L, Farago AF, Schultz KR, Ferris LA, Piotrowska Z, Hardwick J, Huang D, Mino-Kenudson M, Iafrate AJ, Hata AN, Yeap BY, Shaw AT (2017) Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small-cell lung cancer. JCO precision oncology 201710.1200/PO.17.00063 ↗

64. Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC (2020) Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials. Lancet Oncol 21:261–27010.1016/S1470-2045(19)30690-4 ↗

65. Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 21:271-28210.1016/S1470-2045(19)30691-6 ↗

66. Johnson TW, Richardson PF, Bailey S, Brooun A, Burke BJ, Collins MR, Cui JJ, Deal JG, Deng YL, Dinh D, Engstrom LD, He M, Hoffman J, Hoffman RL, Huang Q, Kania RS, Kath JC, Lam H, Lam JL, Le PT, Lingardo L, Liu W, McTigue M, Palmer CL, Sach NW, Smeal T, Smith GL, Stewart AE, Timofeevski S, Zhu H, Zhu J, Zou HY, Edwards MP (2014) Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem 57:4720–474410.1021/jm500261q ↗

67. Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, Gainor JF, Johnson M, Dietrich J, James LP, Clancy JS, Chen J, Martini JF, Abbattista A, Solomon BJ (2017) Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol 18:1590–159910.1016/S1470-2045(17)30680-0 ↗

68. Shaw AT, Solomon BJ, Chiari R, Riely GJ, Besse B, Soo RA, Kao S, Lin CC, Bauer TM, Clancy JS, Thurm H, Martini JF, Peltz G, Abbattista A, Li S, Ou SI (2019) Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial. Lancet Oncol 20:1691–170110.1016/S1470-2045(19)30655-2 ↗

69. Papin C, Denouel-Galy A, Laugier D, Calothy G, Eychène A (1998) Modulation of kinase activity and oncogenic properties by alternative splicing reveals a novel regulatory mechanism for B-Raf. J Biol Chem 273:24939–2494710.1074/jbc.273.38.24939 ↗

70. Imyanitov EN, Iyevleva AG, Levchenko EV (2021) Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives. Crit Rev Oncol Hematol 157:10319410.1016/j.critrevonc.2020.103194 ↗

71. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855–86710.1016/S0092-8674(04)00215-6 ↗

72. Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, Han B, Cao Q, Cao X, Suleman K, Kumar-Sinha C, Dhanasekaran SM, Chen YB, Esgueva R, Banerjee S, LaFargue CJ, Siddiqui J, Demichelis F, Moeller P, Bismar TA, Kuefer R, Fullen DR, Johnson TM, Greenson JK, Giordano TJ, Tan P, Tomlins SA, Varambally S, Rubin MA, Maher CA, Chinnaiyan AM (2010) Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 16:793–79810.1038/nm.2166 ↗

73. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–95410.1038/nature00766 ↗

74. Tan YH, Liu Y, Eu KW, Ang PW, Li WQ, Salto-Tellez M, Iacopetta B, Soong R (2008) Detection of BRAF V600E mutation by pyrosequencing. Pathology 40:295–29810.1080/00313020801911512 ↗

75. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–251610.1056/NEJMoa1103782 ↗

76. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, Veronese ML, Tabernero J, Baselga J (2015) Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 373:726–73610.1056/NEJMoa1502309 ↗

77. Chacim S, Monjardino T, Cunha JL, Medeiros P, Redondo P, Bento MJ, Mariz JM (2022) Costs, effectiveness, and safety associated with Chimeric Antigen Receptor (CAR) T-cell therapy: results from a comprehensive cancer center. PLoS One 17:e027895010.1371/journal.pone.0278950 ↗

78. Gautschi O, Milia J, Cabarrou B, Bluthgen MV, Besse B, Smit EF, Wolf J, Peters S, Früh M, Koeberle D, Oulkhouir Y, Schuler M, Curioni-Fontecedro A, Huret B, Kerjouan M, Michels S, Pall G, Rothschild S, Schmid-Bindert G, Scheffler M, Veillon R, Wannesson L, Diebold J, Zalcman G, Filleron T, Mazières J (2015) Targeted therapy for patients with BRAF-mutant lung cancer: results from the European EURAF cohort. J Thorac Oncol : Off Publ Int Assoc Study Lung Cancer 10:1451–145710.1097/JTO.0000000000000625 ↗

79. Planchard D, Kim TM, Mazieres J, Quoix E, Riely G, Barlesi F, Souquet PJ, Smit EF, Groen HJ, Kelly RJ, Cho BC, Socinski MA, Pandite L, Nase C, Ma B, D’Amelio A Jr, Mookerjee B, Curtis CM Jr, Johnson BE (2016) Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol 17;642-65010.1016/S1470-2045(16)00077-2 ↗

80. Han J, Liu Y, Yang S, Wu X, Li H, Wang Q (2021) MEK inhibitors for the treatment of non-small cell lung cancer. J Hematol Oncol 14:110.1186/s13045-020-01025-7 ↗

81. Fischmann TO, Smith CK, Mayhood TW, Myers JE, Reichert P, Mannarino A, Carr D, Zhu H, Wong J, Yang RS, Le HV, Madison VS (2009) Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors. Biochemistry 48:2661–267410.1021/bi801898e ↗

82. Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, Hu LL (2020) ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med 19:1997–2007

83. Hainsworth JD, Cebotaru CL, Kanarev V, Ciuleanu TE, Damyanov D, Stella P, Ganchev H, Pover G, Morris C, Tzekova V (2010) A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol : Off Publ Int Assoc Study Lung Cancer 5:1630–163610.1097/JTO.0b013e3181e8b3a3 ↗

84. Jänne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, Franke FA, Grinsted L, Zazulina V, Smith P, Smith I, Crinò L (2013) Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 14:38–4710.1016/S1470-2045(12)70489-8 ↗

85. Soria JC, Fülöp A, Maciel C, Fischer JR, Girotto G, Lago S, Smit E, Ostoros G, Eberhardt WEE, Lishkovska P, Lovick S, Mariani G, McKeown A, Kilgour E, Smith P, Bowen K, Kohlmann A, Carlile DJ, Jänne PA (2017) SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer. Ann Oncol : Off J Eur Soc Med Oncol 28:3028–303610.1093/annonc/mdx628 ↗

86. Hellmann MD, Kim TW, Lee CB, Goh BC, Miller WH Jr, Oh DY, Jamal R, Chee CE, Chow LQM, Gainor JF, Desai J, Solomon BJ, Das Thakur M, Pitcher B, Foster P, Hernandez G, Wongchenko MJ, Cha E, Bang YJ, Siu LL, Bendell J (2019) Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. Ann Oncol : Off J Eur Soc Med Oncol 30:1134–114210.1093/annonc/mdz113 ↗

87. Oxnard GR, Yang JC, Yu H, Kim SW, Saka H, Horn L, Goto K, Ohe Y, Mann H, Thress KS, Frigault MM, Vishwanathan K, Ghiorghiu D, Ramalingam SS, Ahn MJ (2020) TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann Oncol : Off J Eur Soc Med Oncol 31:507–51610.1016/j.annonc.2020.01.013 ↗

88. Amoresano A, Incoronato M, Monti G, Pucci P, de Franciscis V, Cerchia L (2005) Direct interactions among Ret, GDNF and GFRalpha1 molecules reveal new insights into the assembly of a functional three-protein complex. Cell Signal 17:717–72710.1016/j.cellsig.2004.10.012 ↗

89. Li AY, McCusker MG, Russo A, Scilla KA, Gittens A, Arensmeyer K, Mehra R, Adamo V, Rolfo C (2019) RET fusions in solid tumors. Cancer Treat Rev 81:10191110.1016/j.ctrv.2019.101911 ↗

90. Song Z, Yu X, Zhang Y (2016) Clinicopathologic characteristics, genetic variability and therapeutic options of RET rearrangements patients in lung adenocarcinoma. Lung cancer (Amsterdam, Netherlands) 101:16–2110.1016/j.lungcan.2016.09.002 ↗

91. Wang R, Hu H, Pan Y, Li Y, Ye T, Li C, Luo X, Wang L, Li H, Zhang Y, Li F, Lu Y, Lu Q, Xu J, Garfield D, Shen L, Ji H, Pao W, Sun Y, Chen H (2012) RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol : Off J Am Soc Clin Oncol 30:4352–435910.1200/JCO.2012.44.1477 ↗

92. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J, Chou YC, Joly AH (2011) Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10:2298–230810.1158/1535-7163.MCT-11-0264 ↗

93. Wakelee HA, Gettinger S, Engelman J, Jänne PA, West H, Subramaniam DS, Leach J, Wax M, Yaron Y, Miles DR, Lara PN Jr (2017) A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 79:923-93210.1007/s00280-017-3283-z ↗

94. Cheng Z, Li M, Dey R, Chen Y (2021) Nanomaterials for cancer therapy: current progress and perspectives. J Hematol Oncol 14:8510.1186/s13045-021-01096-0 ↗

95. Amreddy N, Babu A, Muralidharan R, Panneerselvam J, Srivastava A, Ahmed R, Mehta M, Munshi A, Ramesh R (2018) Recent advances in nanoparticle-based cancer drug and gene delivery. Adv Cancer Res 137:115–17010.1016/bs.acr.2017.11.003 ↗

96. Allen TM, Cullis PR (2013) Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 65:36–4810.1016/j.addr.2012.09.037 ↗

97. Zhou J, Zhao WY, Ma X, Ju RJ, Li XY, Li N, Sun MG, Shi JF, Zhang CX, Lu WL (2013) The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer. Biomaterials 34:3626–363810.1016/j.biomaterials.2013.01.078 ↗

98. Koo OM, Rubinstein I, Onyuksel H (2005) Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomed Nanotechnol Biol Med 1:193–21210.1016/j.nano.2005.06.004 ↗

99. Lee W-H, Loo C-Y, Traini D, Young PM (2015) Inhalation of nanoparticle-based drug for lung cancer treatment: advantages and challenges 10:481–48910.1016/j.ajps.2015.08.009 ↗

100. Borse VB, Konwar AN, Jayant RD, Patil PO (2020) Perspectives of characterization and bioconjugation of gold nanoparticles and their application in lateral flow immunosensing. Drug Deliv Transl Res 10:878–90210.1007/s13346-020-00771-y ↗